Podcasts about ranbaxy

In this inspiring episode of The Brand Called You, we have Rohit Chanana—seasoned corporate leader, investor, and author of DIl SE DOST. With 37 years across Escorts, Ranbaxy, and Hero Group, Rohit reveals game-changing leadership philosophies rooted in trust, gratitude, and empathy, now captured in his compelling new book. A must-listen for aspiring leaders and entrepreneurs.00:38- About Rohit ChananaRohit is the founder of Sarcha Advisors.He's the author of a book which is titled 'Dil Se Dost'.

In the latest episode of Inside Forbes India Podcast, Naini Thaker discusses her deep-dive profile on Dilip Shanghvi, the low-key founder of Sun Pharma, India's largest pharmaceutical company. Starting with just $200, Shanghvi's strategic focus on chronic therapies and high-value acquisitions—most notably Ranbaxy—helped shape Sun Pharma into a global force. The conversation explores how the company weathered challenges, such as price erosion, by doubling down on R&D and pivoting toward complex speciality drugs. It also highlights that Shanghvi's leadership is marked by humility, passion for his work, and a focus on patient care rather than wealth accumulation.

In this episode of Let's Combinate, host Subhi Saadeh, a seasoned quality professional, delves into the concept of 'everyone owns quality' and explains why this notion is flawed. Subhi recalls his eye-opening experience with Joanna Gallant's article on quality ownership and discusses the importance of clear accountability within organizations. The episode emphasizes that while all employees play a role in quality, true ownership lies with top management. Subhi also highlights regulatory frameworks like ISO 13485 and 21 CFR 820, noting how they mandate management's responsibility for quality systems. The discussion extends to real-world examples, including the Ranbaxy scandal, to illustrate the dire consequences of poor quality management. The episode concludes with a call to shift the mindset from 'everyone owns quality' to 'leadership owns quality.' 00:00 Introduction to Quality Ownership04:10 Regulatory Frameworks and Quality Management05:14 The Flaws in 'Everyone Owns Quality'06:45 Case Study: Ranbaxy Laboratories08:49 The Importance of a Strong Quality CulturePrevious Episodes:Joanna Gallant: https://www.letscombinate.com/076-gmp-training-competence-human-error-and-mentorship-with-joanna-gallant/Katherine Eban: https://www.letscombinate.com/115-bottle-of-lies-generic-drugs-quality-ranbaxy-audits-and-inspiring-quality-pros-with-nyt-be/Links: ICH Q10: https://database.ich.org/sites/default/files/Q10%20Guideline.pdfISO13485: https://www.iso.org/standard/59752.html21CFR820: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-820/subpart-B/section-820.20BBC Article: https://www.bbc.com/news/world-asia-india-22520953Bottle of Lies: https://www.amazon.com/Bottle-Lies-Inside-Story-Generic/dp/0062338781Subhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.

Journalist Katherine Eban's investigation over more than ten years has uncovered one of the most shocking medical scandals imaginable, which affects millions of patients across the world. In this podcast, she discusses the shocking reality of what happens or perhaps more accurately what doesn't happen, when generic drugs that we import, are manufactured in countries with poor regulations. When a drug is first approved, it is released with its own brand name, but once the drug's  patent expires, then other manufacturers are allowed to make cheaper generic versions of the same medication. Now most patients and indeed many doctors think these generic drugs are the same as the brand name ones - but they are not. Current regulations only require the medications to be "bioequivalent" and they also allowed to have very different absorption rates, so may work very differently to the brand name pharmaceuticals, which has huge implications for patients. But although that is worrying enough, many of the world's generic drugs are made in India and China - where as Katherine explains -  there is little regulation and they can be made very cheaply. In what was India's largest pharmaceutical company – Ranbaxy - 200 of its generic drugs were revealed to have been filed with the US drug regulator, the FDA, with inadequate, falsified or completely missing data. And furthermore in other companies, an FDA investigator found in over 80 plants in India and China he visited, 80% had falsified data. These generic drugs are sold into every country, so may well end up on the shelves of your local pharmacy, so what can we do as patients and doctors to protect ourselves? On her website, Katherine gives some tips for consumers in  A Guide To Investigating Your Own Drugs. Bottle of Lies: Ranbaxy and the Dark Side of Indian Pharma by Katherine Eban is published by Juggernaut. The host of this award nominated podcast, Liz Tucker is an award winning medical journalist and former BBC producer and director.  You can follow Liz on Twitter at https://twitter.com/lizctucker and read her Substack newsletter about the podcast at https://liztucker.substack.com If you would like to support this podcast you can do so via Patreon at https://www.patreon.com/WhatYourGPDoesntTellYou or via PayPal at https://www.whatyourgpdoesnttellyou.com/support/

On this episode, I was joined by Katherine Eban, the New York Times best-selling author of "Bottle of Lies". In this episode, Katherine dives deep into her decade-long investigation into the quality issues prevalent in generic drug manufacturing overseas. Eban highlights the need for improving transparency in the pharmaceutical industry. She shares some inspiring stories of dedicated professionals in the industry who strive to ensure patients receive quality. Eban also discusses her findings on fraudulent practices in manufacturing plants and the role of quality data in drug production. The episode sheds light on the importance of understanding the manufacturing process behind generic drugs and critical quality control issues needing urgent attention. Time-Stamps: 02:12 The Start of the Investigation into Generic Drug Quality 08:59 The Impact of Quality Issues on Global Health 12:54 Understanding the FDA's Role in Drug Quality Control 16:55 The Struggle to Maintain Quality in the Pharmaceutical Industry 18:39 The Ranbaxy Story 27:45 Peter Baker 30:19 Quality Stories 33:27 Conclusion and Final Thoughts Link to Katherine's Book: Bottle of Lies: The Inside Story of the Generic Drug Boom, is a New York Times bestseller and one of the New York Times' 100 Notable Books of 2019.

ניסינו להבין מה מונע ממערכת הבריאות להיות טובה, יעילה וכל זה בעלות נמוכה יותר.במהלך השיחה ענינו על השאלות הבאות: מדוע בית חולים בלוס אנג'לס הוציא בממוצע 104 אלף דולר על כל מטופל, בזמן שבית חולים בסן פרנסיסקו הוציא כמחצית מכך? ובאיזה מבתי החולים שיעורי התמותה היו גדולים יותר? מדוע משרד הבריאות הישראלי מסרב לאשר תכנית לאשפוזי בית שתצמצם את העומס על בתי החולים ותשפר את סיכוי ההחלמה של החולים, וכל זאת מבלי שהממשלה תגדיל את תקציב הבריאות? מי מזהה בדיוק רב יותר גידולים סרטניים - הרדיולוגים או הבינה המלאכותית? כיצד חברת התרופות Ranbaxy ההודית מכרה תרופות שיש בהן שברי זכוכיות? בשיחה ענינו על כל השאלות הללו, ואף עסקנו בשאלות חשובות נוספות. Support the showלצפיה ברשימת ההמלצותלתמיכה ותרומות להפקת הפודקאסט וביצוע מנויהאזנה נעימה!

Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women's Hospital, and Co-Director of the Center for Infection and Immunity, at the Brigham Research Institutes, Boston. He is also an associate member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women's Hospital. His major research interests include autoimmune diseases—particularly the role of co-stimulation—the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, as well as cell surface molecules and regulatory factors that regulate the induction of T cell tolerance and dysfunction. His laboratory bred several transgenic mice that serve as animal models for human multiple sclerosis. The Kuchroo laboratory was also the first to describe the TIM family of genes, and identified Tim-3 as an inhibitory receptor expressed on T cells, which is now being exploited for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which have been shown to induce multiple different autoimmune diseases in humans. Kuchroo is the lead author on a paper describing the development of Th17, which is one of the most cited papers in the field of Immunology.Kuchroo came to the United States in 1985, as a Fogarty International Fellow at The National Institutes of Health, Bethesda, MD for one year, before joining the department of pathology at Harvard Medical School, as a research fellow. Later, he joined the Center for Neurologic Diseases at Brigham and Women's Hospital as a junior faculty member in 1992.He obtained his degree in Veterinary Medicine from the College of Veterinary Medicine, Hisar, India. Subsequently, he specialized in pathology at the University of Queensland, Brisbane Australia, where he obtained a Ph.D. in 1985. He received the Fred Z. Eager Research Prize and medal for his Ph.D. research work at the University of Queensland. Based on his contributions, he was awarded the Javits Neuroscience Award by the National Institutes of Health in 2002 and the Ranbaxy prize in Medical Research from the Ranbaxy Science Foundation in 2011. He was named Distinguished Eberly Lecturer in 2014, and obtained a Nobel Laureate Peter Doherty Lecture/Prize in 2014.Kuchroo has 25 patents and has founded 5 different biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals. He also serves on the scientific advisory boards and works in advisory capacity to a number of internationally recognized pharmaceutical companies including: Biocon, Syngene, Pfizer, Novartis and Glaxo-Smith-Klein (GSK).Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

In this episode of Explain Like I'm 10, our host Meghnad speaks with the co-authors of the book "The Truth Pill" Dinesh S Thakur & Prashant Reddy T. They are joined by comedian & writer Hoshang Maini who is our manifestation of a YouTube comment. Together, they discuss how safe Indian medicines are, how drugs are regulated in India, and how laws & policies can align to ensure public health security. Tune in for information you need to know before you swallow another pill! Follow Dinesh on Twitter: https://twitter.com/d_s_thakur?t=gD_ns2orin0eymrF2WyeKw&s=08 Follow Prashant on Twitter: https://twitter.com/Preddy85?t=Fk-ux_EF4i6GL5Z9OX5pNw&s=08 Follow Hoshang on Instagram: https://www.instagram.com/hoshangmaini/?igshid=YmMyMTA2M2Y%3D Subscribe to us on YouTube: https://www.youtube.com/channel/UC0sxICr-rvhR9dvBsx4uoTA Find our host Meghnad on his social handles YouTube: https://www.youtube.com/@meghnerd Instagram: https://www.instagram.com/meghnads/?hl=en Twitter: https://twitter.com/Memeghnad?s=20&t=Gc1ww3EvNh-6TNEcFD76Pw LinkedIn: https://www.linkedin.com/in/meghnad-s-83278a18b/?originalSubdomain=in Connect with us at: allaboutnow@pratilipi.com Know more about the book here: thetruthpill.in  See omnystudio.com/listener for privacy information.

The Gambian cough syrup tragedy in which 66 children died has once again raised alarm about India's drug regulation policy. But was Gambia just one rotten apple? Or this apple cart itself full of loopholes? In this episode Dinesh Thakur, who became famous as a whistleblower against Ranbaxy, joins Sandip Roy to talk about his book The Truth Pill (co-written by Prashant Reddy) which looks at the state of drug regulation in India, and whether we actually get what we ordered when we buy medicines in India.

Former Ranbaxy promoters Malvinder Singh and Shivinder Singh were sent to jail for six months by the Supreme Court -- which also ordered an audit of the Fortis-IIH deal. This is not the first time the brothers have been in the news for a wrong reason. This latest development is one more chapter in the long drawn-out story of their downfall. In today's segment, we offer a peek into the journey of the Singh brothers.  The draft Drugs, Medical Devices and Cosmetics Bill, 2022 -- which seeks to replace a 1940 law -- claims to set several things right in the pharma sector. It may also avert a Ranbaxy like scandal too. Meanwhile, another draft bill put out by the government this week seeks to address problems in the telecom sector. The draft Indian Telecommunications 2022 bill, which once framed into Act, may have far reaching effects on OTT communication services like WhatsApp, spectrum allocations and several other fields.  Meanwhile, gold prices have been spiraling southwards after it peaked in March this year, as global central banks joined hands to raise interest rates to tame inflationary pressures. With the US Federal Reserve lifting its policy rate by 75 basis points for the third consecutive time, analysts believe that the yellow metal will continue to face pressure in the near-term as well.  Thanks to the internet, we will get the factory and services data of the UK and Euro zone within seconds of their release. But have you ever noticed the difference between download and upload speeds? A simple speed test will tell you that the upload speed is usually lower than the download. Let us find out why in this episode of the podcast.     

Before we get into the details of the current case, let's learn some history. In the 1980s, Parvinder Singh inherited Ranbaxy from his father, Bhai Mohan Singh, a wealthy contractor who hailed from Rawalpindi. What had started out as a small pharma business in Amritsar had by then grown into an empire. At a time when most Indian drug-makers were looking inwards, Parvinder decided to take Ranbaxy into international markets. By the time he passed away in 1999, he left behind a global pharma major. And, the way in which Parvinder's sons, Malvinder and Shivinder Singh, squandered away the empire in subsequent years has become the stuff of corporate folklore. According to reports, Malvinder and Shivinder squandered away Rs 22,500 crore over the span of just one decade. So, what are the particulars of the case in which the latest orders have come? Former Ranbaxy promoters Malvinder and Shivinder Singh have been accused of concealing information about wrongdoings at Ranbaxy when they sold a majority stake in it to Daiichi Sankyo, a Japanese firm, in 2008. In 2016, the Singapore tribunal awarded Daiichi Rs 3,500 crore in damages. In 2018, Daiichi Sankyo approached the Indian Supreme Court with the allegation that the Singh brothers were diverting funds using a number of shell companies to avoid the payments. Daiichi had also approached the apex court to stop a deal between Fortis and Malaysia-based IHH Group. As part of the deal, the IHH Group was set to acquire a 30 per cent stake in the Fortis group for 1.1 billion dollars with an open offer of 26 per cent stake. While the deal was signed in August 2018, the SC stayed the IHH open offer in December that same year. But, this too is only the tip of the proverbial iceberg since there are several other cases against the Singh brothers. In October of 2019, Malvinder and Shivinder were arrested by the Economic Offenses Wing of the Delhi Police for allegedly diverting money and causing losses to the tune of Rs 2,397 crore. The allegations were related to Religare Enterprises Limited, or REL, a company that was once led by the brothers. They were accused of diverting money from Religare Finvest Limited, or RFL, an REL subsidiary. According to the allegations, the brothers and other REL officials took loans in RFL's name and then diverted the money to other firms. In 2019, the Serious Fraud Investigation Office, or SFIO, was also probing their role in an alleged fund diversion at Fortis Healthcare. After its initial probe, the SFIO had said that it believed that the fraud could be to the tune of Rs 2,000 crore. The Securities and Exchange Board of India and the SFIO suspected that the Singh brothers had diverted public money from Fortis Healthcare to Gurinder Singh Dhillon, the head of Radha Soami Satsang Beas and other religious bodies. Long before the recent wranglings, there was also the episode with Dinesh Thakur, the whistle-blower who put Ranbaxy in the dock. Thakur joined Ranbaxy in 2003. But, in 2005, Thakur quit and waved a red flag about alleged violations and irregularities at the pharma company. Thakur ended up working with US authorities to expose the fraud and even filed a lawsuit to hold Ranbaxy accountable. Eventually, Ranbaxy pleaded guilty to making fraudulent statements to US regulatory authorities about how it tested drugs at its Indian plants. The firm had to pay $500 million to resolve the civil and criminal violations. It remains to be seen if the recent developments will be the final chapter of their downfall, or whether more skeletons might tumble out of their cupboard. What we know for sure is that Malvinder and Shivinder Singh have all but destroyed the legacy of their grandfather Bhai Mohan Singh and father Parvinder. 

e.015 thinks https://www.linkedin.com/in/sreekant/ (Sree Kant) is pretty phenomenal. Sree is an experienced biotech executive, and company builder. Over a 20-year career in life sciences and healthcare, he has worked across investing, operational, advisory, and entrepreneurial roles and functions. He is passionate about translating cutting edge science into therapies that significantly change health outcomes for patients. Before founding https://bakxtx.com/ (BAKX), Sree headed the Investments and Partnerships function at Life Biosciences, where he built platform focused companies in the areas of age-related diseases. He also took on operational roles in the portfolio companies driving the corporate development agenda. Prior to Life bio, Sree led early partnering strategy for https://www.pfizer.com/ (Pfizer), driving strategic partnerships across different therapeutic areas/technologies and geographies. He also built Pfizer's early target partnering vehicle and drove academic partnerships and spinouts to advance novel target platforms. Sree was also Principal at the https://www.bcg.com/ (Boston Consulting Group) advising large pharma, biotech, and medical device companies in areas of Corporate development, R&D strategy, M&A, etc.  Sree started his career with Ranbaxy labs in New Delhi and London, and also was a founding member of India's first preventative, managed health company. Sree has an MBA from the Indian Institute of Management, and an MPH from the Harvard School of Public Health.

When we pick up medicine from our nearby chemist, we assume that we are getting what we pay for. That trust may be misplaced. Dinesh Thakur joins Amit Varma in episode 245 of The Seen and the Unseen to share the story of the Ranbaxy fraud, and the shoddy state of Indian pharma today. Also check out: 1. Dinesh Thakur's foundation, blog and Twitter. 2. Bottle of Lies : Ranbaxy and the Dark Side of Indian Pharma -- Katherine Eban. 3. The Impact of Regulatory Structure on Quality of Medicines in India -- Talk by Dinesh Thakur. 4. Dinesh Thakur interviewed by News Laundry, Lallantop and The Accad and Koka Report. 5. The Indian pharmaceutical industry is in denial over drug-quality charges -- Dinesh Thakur. 6. Pharma industry's playbook on low-quality drugs -- Dinesh Thakur and Prashant Reddy Thikkavarapu. 7. India's drug regulator has failed the pandemic stress test -- Dinesh Thakur. 8. In generic drug plants in China and India, data falsification is still a problem -- Katherine Eban and Sony Salzman. 9. Healing the Pharmacy of the World -- KL Sharma. 10. The Gita Press and Hindu Nationalism -- Episode 139 of The Seen and the Unseen (w Akshaya Mukul). 11. Science and Covid-19 -- Episode 221 of The Seen and the Unseen (w Anirban Mahapatra). 12. Slow Ideas -- Atul Gawande. 13. Understanding Indian Healthcare -- Episode 225 of The Seen and the Unseen (w Karthik Muralidharan). 14. The Economics and Politics of Vaccines -- Episode 223 of The Seen and the Unseen (w Ajay Shah). 15. We Must Save Our Farmers -- Amit Varma. 16. ‘Killer cough syrup' maker failed quality tests several times -- Times of India report on the Jammu deaths. 17. Why lethal cough syrup slipped past the law -- Prabha Raghavan and Arun Sharma. 18. COVID-19: Hundreds Of Clinical Trials Under Way In India, Many Lack Rigour, Say Experts -- Anoo Bhuyan. 19. Clinical trial database hole -- GS Mudur. 20. CDSCO faces CIC ire over ‘misplaced' 2013 report on ‘irregular' approval to drugs -- Prabha Raghavan. 21. A Report on Drug Regulator CDSCO's ‘Irregular' Approvals Has Gone ‘Missing' -- The Wire staff. 22. New CDSCO Disclosure Reveals Quality of Medicines Sold in India -- Samir Malhotra. 23. On US blacklist, in India they are in the grey zone -- Ritu Sarin, Kaunain Sheriff M and Jaz Mazoomdar. 24. Poor quality drugs caused Niloufer maternal deaths: Doctors' panel -- Syed Akbar. 25. 2014 Bilaspur tubectomy deaths: Absconding pharma firm director held -- PTI news report. 26. Clinical Trials in India Need Better Regulations -- Shah Alam Khan. 27. Mozambique raises quality concerns on Indian drug exports -- Deepak Patel. 28. Drug regulation: 27 medicines sold by top firms ‘fail' quality tests in seven states -- Deepak Patel. 29. 39 Indian drug companies blacklisted by Vietnam -- Pranshu Rathi. 30. Drugs with carcinogenic toxins: banned elsewhere, sold in India -- Priyanka Pulla. This episode is sponsored by CTQ Compounds. Check out The Daily Reader, FutureStack and The Social Capital Compound. Use the code UNSEEN for Rs 2500 off. Please subscribe to The India Uncut Newsletter. It's free! And check out Amit's online course, The Art of Clear Writing.

This week we are taking a look at the Singh brothers. Malvinder Mohan Singh and Shivinder Mohan Singh the heirs to a generic pharmaceutical company that would be responsible for providing Africans with AIDS, junk drugs. A major source for this episode was A Bottle of Lies: The Inside Story of the Generic Drug Boom by Katherine Eban. Sean is slowly being radicalized by RFK so a significant portion is spent on new theories as to why the world sucks. All that and more right here on Grubstakers. Check out Grubstakers.net for a full list of our resources on this and every other episode. Enjoy!

Supply Chain is one of the largest working networks in the world. It essentially encompasses the entire system from production to the sale of a product. It is an indispensable part of any business. Supply Chain Management presents some of the largest employment opportunities to a number of working sectors. The pharma industry has highly benefited from the working of supply chains. The Brand Called You is back for a brand new season with stories of hundreds of talented professionals. Our newest addition is the ‘Supply Chain Gurus' series. And today on the podcast we have supply chain expert Govind Jaju! Tune in for a very interesting discussion around supply chains and the revolutionary changes that technology is bringing about in the supply chain network. Find us on: Facebook - http://facebook.com/followtbcy/ Twitter - http://twitter.com/followtbcy/ Instagram - http://instagram.com/followtbcy/ --- Support this podcast: https://anchor.fm/tbcy/support

In the first of this two part program we heard that nearly 80 percent of the active ingredients of all brand-name and generic drugs as well as almost all antibiotics in the U.S. are made outside of the country without any effective oversight, mostly in China and India. There is growing evidence that many of these drugs can be ineffective at best or contain toxic ingredients. Katherine Eban’s book: “Bottle of Lies” is the detective story - now in the hands of medical staff, FDA administrators and those who fight for disclosure and safer medicines. This program opens with Katherine Eban’s story of Ranbaxy, whose pills, exported into the US and across the world, actually led to the deaths of patients. Nevertheless it took years to close them down. Dr. Harry Lever, is a cardiologist at Cleveland Clinic and a long-time and ongoing collaborator with Katherine Eban. On Jun 4, 2020, he spoke with Lisa Salberg about the safety and use of some generic drugs: The book, Bottle of Lies, by Katherine Eban inspired many of these discussions and the investigative reporting, fact finding and reform movements.

In the first of this two part program we heard that nearly 80 percent of the active ingredients of all brand-name and generic drugs as well as almost all antibiotics in the U.S. are made outside of the country without any effective oversight, mostly in China and India. There is growing evidence that many of these drugs can be ineffective at best or contain toxic ingredients. Katherine Eban’s book: “Bottle of Lies” is the detective story - now in the hands of medical staff, FDA administrators and those who fight for disclosure and safer medicines. This program opens with Katherine Eban’s story of Ranbaxy, whose pills, exported into the US and across the world, actually led to the deaths of patients. Nevertheless it took years to close them down. Dr. Harry Lever, is a cardiologist at Cleveland Clinic and a long-time and ongoing collaborator with Katherine Eban. On Jun 4, 2020, he spoke with Lisa Salberg about the safety and use of some generic drugs: The book, Bottle of Lies, by Katherine Eban inspired many of these discussions and the investigative reporting, fact finding and reform movements.

Investigative journalist, Katherine Eban, on her book Bottle of Lies that documents global fraud, large-scale data fabrication and unsafe practices inside Indian drug plants.

90 percent of the world’s pharmaceutical market is comprised of generic drugs. Generics have been hailed as low-cost alternatives to their more expensive brand-name counterparts, thereby providing low-income patients around the world with affordable medicines.An explosive new book, Bottle of Lies: The Inside Story of the Generic Drug Boom, by journalist Katherine Eban demolishes this myth and provides a dizzying, page-turning investigation of the lies, deceit, and outright fraud that run rampant in the generics industry. The narrative arc of the book is built around the rapid rise and the dramatic decline of the Indian generics manufacturer Ranbaxy.This week, Milan speaks with Katherine to discuss her decade-long investigation, the contested role that India plays, and the consequences for public health.

Dinesh Thakur Generic drugs represent 90% of the pharmaceutical market. Their use has been encouraged through decades of favorable legislation and subsidies, with authorities claiming they are as safe and effective as brand name drugs. Yet generic preparations tainted with impurities are being reported with increasing frequency. What should doctors and the public know about generic drug manufacture? Our guest is the chemist who was at the center of the most important scandal to rock the global pharmaceutical industry in decades. GUEST: Dinesh Thakur https://twitter.com/d_s_thakur (Twitter) and http://dineshthakur.com/ (Website) LINKS: https://www.katherineeban.com/ (Bottles of Lies) by Katherine Eban RELATED EPISODES: https://accadandkoka.com/episode15/ (Ep. 15 Lethal Regulation: The 1962 FDA Amendments) (with guest Mary Ruwart) SUPPORT THE SHOW: https://www.patreon.com/accadandkoka (Make a small donation) on our Patreon page on and join our discussion group or receive a free book. WATCH THE SHOW: https://youtu.be/MbAiwRImqsE (Watch the episode) on our YouTube channel Support this podcast

Yesterday, Finance Minister Nirmala Sitharaman assured the Punjab and Maharashtra Co-operative (PMC) bank account holders that the government and the RBI were on an urgent basis looking to resolve the ongoing restrictions that have been imposed on the bank. The restrictions on the bank had been put two days after its former managing director, Joy Thomas, admitted to fraud in a letter he wrote to the RBI. In the first segment, Udit Misra, who writes on the economy for the Indian Express, explains what the PMC bank scam is about, how it managed to go undetected for eleven years and the questions it raises about the banking system and the RBI.  Next, Vishnu Varma, Indian Express's Kerala correspondent talks about the 47-year-old woman named Jolly Joseph who has been arrested for allegedly murdering her husband, parents in law, and three other members of the extended family by giving them cyanide in food over a period of 14 years. And last, why the Economic Offence Wing of the Delhi Police arrested the former promoter of Religare Enterprises, Shivinder Singh.

September quarter earnings and global cues will be the top factors guiding the markets today. Industry leader Tata Consultancy Services (TCS) yesterday reported weaker than expected numbers in the September quarter, indicating that double-digit growth may elude the Mumbai-based IT services company in FY20. This is despite record deal closures in several quarters. In Q2, TCS posted a net profit of Rs 8,042 crore, a 1.8 per cent rise over the corresponding period of the previous financial year while net profit declined by 1 per cent in sequential terms. About eight companies, including Infosys, are scheduled to release their September quarter earnings. Analaysts expect Infosys to further upgrade its revenue guidance for the current financial year when it reports its September quarter results later today. They said the Bengaluru-headquartered IT company remains on a firm footing given the recent deal momentum, strong positioning in clients and favourable arithmetic. You can read the full preview on what to expect from the results on our website. That apart, investors will also track industrial production data for the month of August slated to be released today after market hours. Globally, the hope that the US-China trade talks would yield at least a partial deal might boost investors' risk appetite. Top US and Chinese negotiators met on Thursday for the first time since late July to try to find a way out of a 15-month trade war.  Besides, stock-specific developments, oil price movement, the value of rupee against the dollar and foreign fund flow will steer the market. On Thursday, the S&P BSE Sensex corrected by 298 points or 0.8 per cent to close at 37,880 levels, while the broader Nifty50 index settled at 11,235-mark,down 79 points or 0.7 per cent. The rupee ended flat at 71.06 per US dollar. On the global front, Asian shares were up in early trade on Friday. MSCI’s broadest index of Asia-Pacific shares outside Japan rose 0.5 per cent. Australian shares climbed 0.8 per cent, while Japan's Nikkei stock index gained 0.9 per cent. U.S. stocks rose during the overnight trade on Thursday on US-China trade deal optimism. The Dow Jones Industrial Average gained 0.57 per cent, the S&P 500 rose 0.64 per cent, and the Nasdaq Composite added 0.6 per cent. Early trend on SGX Nifty is also indicating a flat to positive start to the day for domestic indices. In the commodities market, Oil prices rose on Thursday. Global benchmark Brent crude futures settled up 78 cents at $59.10 a barrel.  Top headlines for the day -- >> IRCTC may not boost IPO market amid turmoil in financial sector. According to the industry experts, a pick-up in the activity could be seen only in the first half of the coming year.   >> India pursues China-led trade deal despite domestic opposition. Domestic producers' concerns that repercussions might flood Indian market with cheap Chinese imports. >> Revenue crunch prompts govt to consider GST rate hike on products that fall in the slab of 0 and 5% >> Ranbaxy ex-promoters Malvinder, Shivinder Singh arrested in Rs 740-cr fraud case >> Gem and jewellery export dips almost 8 per cent to Rs 1.3 trillion in first half. Experts says, the industry failed to gain from the US-China trade war. 

In this episode, Katherine Eban, investigative journalist and author of Bottle of Lies, illuminates the prevalence of fraud in generic drug manufacturing which brings into question the idea that generics are identical to brand-name drug as we are lead to believe. Katherine walks us through how this widespread corruption came to be, including the shocking story of one particularly egregious (and unfortunately not uncommon) example of an Indian drug company, Ranbaxy, whose business model was completely dependent on falsifying data in their drug applications to the FDA. We then discuss the subsequent investigation into Indian and Chinese drug manufacturing plants which revealed that nearly 80% of them are tainted with fraud. We conclude this discussion on a positive note with i) how individuals can investigate their own drugs to protect themselves ii) an innovative pharmacy attempting to disrupt the market and iii) some ideas on how to reform to the regulations around generic drugs, the FDA, and more.   We discuss: How Peter found Katherine’s book, and what convinced her to investigate the generic drug industry [5:45]; Branded vs. generic drugs: Why they aren’t the same thing [11:15]; The Food and Drug Administration: Why it was originally created and what it does today [20:45]; How the generic drug industry really got its start in the U.S., and the flaw of the Hatch-Waxman Act [28:20]; PEPFAR: How a well-intentioned plan to help Africa with the AIDS epidemic laid the groundwork for corruption [36:30]; The story of Ranbaxy: An Indian drug company whose business model was fraud and deceit [40:45]; How the FDA approves drugs, the impact of “first to file”, and Peter’s tangent on moral corruption [47:30]; A booming generic drug market and the FDA struggling to keep up [57:15]; Dinesh’s internal investigation finds widespread fraud and falsified data inside Ranbaxy [1:00:15]; Presenting the famous SAR document to Ranbaxy’s board of directors which spells out the company-wide fraud [1:09:15]; Dinesh blows the whistle on Ranbaxy which leads to a raid on their US plant [1:19:45]; Formal investigation of Ranbaxy is launched, but the FDA keeps approving Ranbaxy drug applications [1:33:30]; What role does the culture in India play in the high prevalence of fraud in the drug industry? [1:41:00]; The extreme prevalence of data fraud/manipulation in foreign generic drug factories [1:52:30]; Concluding the Ranbaxy story [2:06:15]; How concerned should you be when buying a generic drug from your local pharmacy? [2:11:15]; How to investigate your own drugs for quality to ensure you are getting what you need [2:18:30]; An innovative pharmacy that tests all its drugs for quality [2:24:45]; Reforming the FDA and generic drug industry: Why we need reform and ideas on how to do it [2:27:45]; The importance of taking individual ownership and not waiting for Congress to bail us out [2:34:00]; Closing thoughts from Katherine [2:36:50]; and More. Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/katherineeban/ Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.

Listen NowNine in 10 prescriptions are today filled using a generic drug saving Americans tens of billions annually.   A significant amount of generic drugs, along with active ingredients in all drugs, are manufactured overseas.  However, how safely or to what quality standards are these ingredients and generics produced?   Bottle of Lies, published in May, tells the story of appalling practices foreign generic manufacturers use to produce these drugs at the most minimal cost.  The work moreover provides a detailed account of Ranbaxy, the former India-based generic manufacturer that after eight years of investigation was fined a then record amount,$500 million, for significant fraud.  The work questions or brings to serious doubt the FDA's ability to adequately inspect overseas generic manufacturers ensuring these drugs are safe for consumption in the US or around the world.  Listeners may recall I interviewed coauthor Paul Weinberg in September 2017 concerning his related work, Blood On Their Hands, How Greedy Companies, Inept Bureaucracy and Bad Science Killed Thousands of Hemophiliacs and Rosemary Gibson this past December concerning her related, China Rx, Exposing the Risk of America's Dependence on China for Medicine. During this 37 minute interview. Ms. Eban provides an overview of Ranbaxy's manufacturing practices revealed by former employee and whistleblower, Dinesh Thakur.  She explains the mindset, termed "Jugaad," used in India to produce generics.  She discusses the adequacy of the 2013 US settlement with Ranbaxy , the role the Japanese firm, Daiichi Sankyo, a  major Ranbaxy stakeholder, the FDA's ability to adequately inspect Ranbaxy and other generic manufacturers around the world, e.g., Cipla and Mylan, recent and future related Congressional action, how poor or inadequate manufacturing practices complicate remedying the drug shortage problem and what precautions consumers or patients can take before consuming generic drugs.  Katherine Eban, an investigative journalist, is a Fortune magazine contributor and Andrew Carnegie fellow. Her articles on pharmaceutical counterfeiting, gun trafficking, and coercive interrogations by the CIA, have won international attention and numerous awards.  She has also written for Vanity Fair, The New York Times, Self, The Nation, the New York Observer and other publications. Her work has been featured on 60 Minutes, Nightline, NPR, and other national news programs.  She lectures frequently on the topic of pharmaceutical integrity.  Her first book, Dangerous Doses: a True Story of Cops, Counterfeiters and the Contamination of America's Drug Supply, was named one of the Best Books of 2005 by Kirkus Reviews and was a Barnes&Noble Discover Great New Writers pick.  Her account of reporting on 9/11 was anthologized in At Ground Zero: 25 Stories From Young Reporters Who Were There. Her work has also been awarded grants from the Alfred P. Sloan Foundation, the Fund for Investigative Journalism, the Alicia Patterson Foundation and the McGraw Center for Business Journalism at CUNY's Craig Newmark Graduate School of Journalism.  Educated at Brown University and Oxford, where she was a Rhodes Scholar.   Information on Bottle of Lies is at: https://www.harpercollins.com/9780062338785/bottle-of-lies/.  Ms. Eban's FAQ regarding how to learn about generics or best to consume is at: https://www.katherineeban.com/faqs.  This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thehealthcarepolicypodcast.com

Good afternoon everyone and welcome to another edition of The Avid Reader. Today our guest is Katherine Eban author of Bottle Of Lies, The Inside Story Of The Generic Drug Boom, published in May by Ecco. Katherine’s resume is too long to recite here, but I’ll give it a go. Katherine is an investigative journalist, a Fortune Magazine contributor and an Andrew Carnegie Fellow as well as a Rhodes scholar. She has also written for Vanity Fair, the NYT, The Nation, the Observer and many other publications. Her previous work, almost a preface to this one, and just as explosive was Dangerous Doses: A True Story of Cops, Counterfeiters, and the Contamination of America’s Drug Supply. She lectures frequently on the topic of pharmaceutical integrity—if there is such a thing. Bottle of Lies is a book that strikes at the heart of the generic drug industry, a behemoth that supplies us formulations that may or may not be equivalent to say Lipitor or Klonopin or Flomax. And these companies control about 90% of our drug supply. Almost all of these companies hail from China or India. This book is especially poignant for me, because for all of my adult life, when a pharmacist asks me if I would like to buy the generic rather than the branded drug, I always ask for the generic. Why? Because it is a lot cheaper!! What I didn’t know, and now sadly do, is that the generic pills I buy may be less effective than the ones made by Glaxo or Smith Kline, or weaker, or tainted or made with tiny slivers of metal inside. One of the many, actually the most egregious of these failures in ethical and FDA standards is Ranbaxy, a company that has failed its customers, has been admonished and fined and still follows nefarious practices. We learn about whistle blowers, inspections that are primarily useless…even learn about Rod Rosenstein..and more incredulously…Mahatma Ghandi! This book will change your life and also scare the crap out of you.

Is it now Modiji vs the gau rakshaks? Prime Minister Narendra Modi broke his silence and came down heavily against the increasing violent attacks by gau rakshaks . But did he answer the question raised in the last episode of NL Hafta — should the fringe be taken seriously? Why are the TV news channels not paying any heed to #ChaloUna, the Dalit march that's taking place right now in solidarity with those who were attacked by gau rakshaks a few weeks ago? Consulting editor, Anand Ranganathan goes to the roots of cow protection vigilantism. Abhinandan Sekhri along with Madhu Trehan, Deepanjana Pal & Manisha Pande discuss The Indian Express report on Ranbaxy judgment by Singapore tribunal, as well as prohibition law in Bihar. And the most important question this week: why did Irom Sharmila’s own people refused to accept after she broke her 16-year long fast? Plus, don't miss the song dedicated to Modiji from gau rakshaks.For reference links, Please visit: http://www.newslaundry.com/2016/08/12/hafta-80-modi-vs-the-gau-rakshaks/ See acast.com/privacy for privacy and opt-out information.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Listen NowRecently the French government fined Sanofi $53 million for what it called a smear campaign against a competitor drug manufacturer.   Ranbaxy was fined $500 million, in part, for making false statements to the FDA.   Last year the pharamaceutical industry in sum paid out $5.5 billion to resolve fraudulent marketing practices.  These included $3 billion in fines against GlaxoSmithKline (GSK) and $762 million against Amgen.   When these settlements were reached eight of the top 10 global pharmaceutical companies were under "corporate integrity agreements"  (that require companies to report compliance activities via an independent monitor for five years).   With governments recouping only a portion of drug company profits via these marketing practices many say pharma simply views the fines as a cost of doing business.  (The day the GSK fine was announced, the largest of its kind in history, GSK's stock price actually closed up).During this 23-minute interview Dr. Fugh-Berman discusses the types and pervasiveness of pharmaceutical marketing abuses, the public health consequences thereof, the adequacy of corporate integrity agreements and other efforts that promise to curb abuse (e.g., the Physician Payment Sunshine Act), her views regarding direct to consumer advertising, Pharmed Out's efforts to better educate (or insulate) physicians, patients and other consumers from marketing manipulation.    Dr. Adriane Fugh-Berman is an Associate Professor in the Department of Pharmacology and Physiology and in the Department of Family Medicine at Georgetown.   She is also Director of PharmedOut a research and education project that promites rational prescribing and exposes the effect of pharmaceutical marketing on prescribing practices.  Previously, Dr. Fugh-Berman was a medical officer in the Contraception and Reproductive Health Branch of the National Institute for Child Health and Human Development at the NIH.  Dr. Fugh-Berman is the former chair of, and currently writes a column for, the National Women's Health Network and she has appeared on 20/20, the Today Show and every major news network.  Dr. Fugh-Berman graduated from Georgetown University School of Medicine and completed a family medicine internship in the Residency Program in Social Medicine at Montefiore Hospital in the Bronx.For information regarding PharmedOut see: http://www.pharmedout.org/. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thehealthcarepolicypodcast.com

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Analjit Singh is the relatively lesser known brother from the Singh parivaar which sold off Ranbaxy to Daichii Sankyo back in 2008. Prince Thomas, the Assistant Editor at Forbes India joins us to talk about the cover story on Analjit Singh, the serial entrepreneur who has learned some lessons from his family feud and is taking adequate care towards relevant corporate governance in his ventures by taking certain interesting steps including induction of independent directors and discouraging his sons and daughters from entering into operations.

Analjit Singh is the relatively lesser known brother from the Singh parivaar which sold off Ranbaxy to Daichii Sankyo back in 2008. Prince Thomas, the Assistant Editor at Forbes India joins us to talk about the cover story on Analjit Singh, the serial entrepreneur who has learned some lessons from his family feud and is taking adequate care towards relevant corporate governance in his ventures by taking certain interesting steps including induction of independent directors and discouraging his sons and daughters from entering into operations.

We are back after getting stuck in a rather unhealthy habit of not being on time. The last month was plump with a number of mergers and acquisitions on a national and an international scale. Spice married Idea in the telecom sector. On the global front, Anil bhais ADAG and MTN, the South African telecom giant are contemplating a merger of sorts, but Mukesh Ambani comes in his younger bro's way yet again. Ranbaxy, the Indian pharmaceutical major has been acquired by its Japanese Counterpart, Daiichi Sankyo in a landmark deal. This season, in India, as the rains pour, so do the mergers.

We are back after getting stuck in a rather unhealthy habit of not being on time. The last month was plump with a number of mergers and acquisitions on a national and an international scale. Spice married Idea in the telecom sector. On the global front, Anil bhais ADAG and MTN, the South African telecom giant are contemplating a merger of sorts, but Mukesh Ambani comes in his younger bro's way yet again. Ranbaxy, the Indian pharmaceutical major has been acquired by its Japanese Counterpart, Daiichi Sankyo in a landmark deal. This season, in India, as the rains pour, so do the mergers.